Novo Nordisk, the Danish pharma behind blockbuster GLP‑1 drugs Wegovy and Ozempic, is re‑tooling its US market growth strategy after a rocky launch. The company plans to borrow tactics from consumer‑goods marketers, aiming to shift perception of its injectable treatments from niche prescriptions to everyday health solutions. The shift includes grocery‑chain tie‑ups and digital ads that make the weekly shot feel as routine as a coffee.

Earlier this year, sales of Wegovy slowed as insurers tightened coverage and physicians hesitated to prescribe a pricey weekly shot. Analysts estimate the U.S. GLP‑1 market could reach $30 billion by 2030, but Novo Nordisk risks losing share to rivals such as Eli Lilly, whose tirzepatide is gaining traction. The firm now eyes brand‑building campaigns and broader retail distribution.

By treating its drugs more like consumer staples, Novo Nordisk hopes to boost adherence and repeat purchases, a shift that could lift its annual revenue beyond $20 billion. Investors will watch whether the new approach translates into higher market penetration or simply adds marketing expense. The company's next quarterly report will reveal if the consumer‑centric play is paying off.